/ Timeline
subject module Timeline
  head =
  / Background
  subject Background
    head = History of Zoonotic Emergence of human coronaviruses is important in understanding the zoonosis relation to the orgin of SARS-CoV-2.
    / Bats
    subject Bats
      head = Coronaviruses have been identified in bats. High contact rate with bats can enable the acquisition and spread of coronavirus
      --
        'Wertheim_et_al_2013
        'Lin_et_al_2017
        'Baucells_et_al_2017
    / Virus Mutation
    subject Mutation
      head = Rates of spontaneous mutation vary amply among viruses. RNA viruses mutate faster than DNA viruses, single-stranded viruses mutate faster than double-strand virus, and genome size appears to correlate negatively with mutation rate.
      -- Mutation of virus
        'Sanjuán_et_al_2016
        'Sanjuán_et_al_2010
        'Duffy_et_al_2018
        'Elena_et_al_2005
    / Human Coronavirus
    subject HumanCoronaviruses
      head = The routine nature of viral cross-species transmission in the coronavirus family brings up the question of the likelihood of another emergence event of a pathogenic human coronavirus and underscores the need to continue zoonotic surveillance
      --
        'Graham_et_al_2010
        'Ren_et_al_2015
        'Corman_et_al_2018
        'Cui_et_al_2018
        'Wong_et_al_2019
        'Ramadan_et_al_2019
    / SARS Emergence
    subject SARS
      head = The origin of the 2003 SARS epidemic and the 2004 mild SARS cases was probably a result of multiple recombination events.
      -- SARS Emergence
        'Shi_et_al_2008
        'Shi_et_al_2008.!a
        'Luk_et_al_2019.!a
        'Holmes_et_al_2004
        'Li_et_al_2005
        'Hou_et_al_2010

  / Origin
  subject Origin
    head = As of now, the original source of viral transmission to humans remains unclear. There are multiple theories related to natural origin, lab created, intermediate host recombination event and virus emergence from the Wuhan Market

    / Genome Sequence
    subject GenomeSequence
      head = Genomic Analysis of SARS-CoV-2 suggest similarity with SARS-CoV and Bat being the natural reservoir of SARS-CoV-2.
      --
        'Brook_et_al_2020
        'Chan_et_al_2020.!q
        'Anderson_et_al_2020
        'Ren_et_al_2020
    / Origin of SARS-CoV-2
    subject CovidOrigin
      head = The original source of viral transmission to humans remains unclear weather COVID-19 has a natural origin or whether the strain became pathogenic before or after the spillover event or it is adapted to human in a lab without genetic engineering.
      -- Origin of SARS-CoV2
        'Ren_et_al_2020
        'Anderson_et_al_2020
        'Guo_et_al_2020
        'Paraskevis_et_al_2020
        'Li_et_al_05_19_2020
        'Li_et_al_05_19_2020.!a
        'Li_et_al_05_19_2020.!b
        'Boni_et_al_03_31_2020
        'Latinne_et_al_05_31_2020
        'Zhou_et_al_06_08_2020
        'Phan_et_al_2020
    / Intermediate Host
    subject IntermediateHost
      head = Differences between the bat coronavirus sampled and SARS-CoV-2,  suggested that humans were infected via an intermediate host, speculating pangalions or civets to be the likely intermediate host. Although subsequent papers have ruled out the possibility of pangolian as an intermediate host.
      -- Pangolin as Host
        'Zhang_et_al_2020h
      -- Civets as Host
        'Wan_et_al_2020.!b
      --
        'Paraskevis_et_al_2020
    / Phylogenetic Analysis
    subject Phylogeny
      head = Phylogenetic analysis reveal that the virus type most closely related to the bat coronavirus was abundant in Guangdong. Findings show that SARS-CoV-2 has not had legitimate recombination and suggests the source of the haplotype in the Huanan Market was imported from elsewhere.
      --
        'Zhang_et_al_2020i
        'Ren_et_al_2020
        'Chan_et_al_2020.!p
    / Wuhan
    subject Wuhan
      head = Early association was observed between the first reported cases of COVID-19 and the Huanan seafood and wildlife market in Wuhan city. However, other research indicates that visitors may have introduced the virus to the market, which then facilitated spread of the infections.
      -- Wuhan
        'Zhou_et_al_2020
        'Riou_et_al_01_24_2020
        'Ji_et_al_2020
        'Wang_et_al_2020c
        'Chan_et_al_2020

  / Epidemic
  subject Epidemic
    head = The earliest case of infection currently known is dated back to 17 November 2019 or possibly 1 December 2019. The virus subsequently spread to all provinces of China and to more than 150 other countries in Asia, Europe, North America, South America, Africa, and Oceania. Human-to-human transmission of the virus has been confirmed in all these regions.
    --
      China
      DiamondPrincess
      SouthKorea
      Singapore
      Iran
      USA
      Europe
    --
      TranmissionLineage
    --
      GlobalEpidemiology

    / China
    subject China
      head = A novel coronavirus designated as 2019-nCoV first appeared in Wuhan, China in late December 2019.
      -- China
        'Phan_et_al_2020
        'Zhu_et_al_2020
        'Huang_et_al_2020
        'Huang_et_al_2020.!a
        'J_et_al_2020
        'J_et_al_2020.!a
        'J_et_al_2020.!b
        'J_et_al_2020.!c
        'Bi_et_al_2020
        'Wu_et_al_2020.!a
        'Chen_et_al_2020c
        'Wu_et_al_2020e
        'Bi_et_al_04_27_2020
    / Diamond Princess
    subject DiamondPrincess
      head = An outbreak of COVID-19 on cruise ship Diamond Princess was reported with 10 initial cases, following an index case on board around 21-25th January. By 20th February, 619 of 3,700 passengers and crew (17%) were tested positive.
      --
        'Russell_et_al_2020
        'Mcmichael_et_al_2020
        'Mcmichael_et_al_2020.!a
        'Mizumoto_et_al_2020
    / South Korea
    subject SouthKorea
      head = The confirmed COVID-19 patients in South Korea are those who came from or visited China.
      --
        'Kim_et_al_2020
        'Lim_et_al_2020
        'Park_et_al_2020
        'Shim_et_al_2020
        'Shim_et_al_2020.!a
    / Singapore
    subject Singapore
      head = As of Feb 15, 2020, 36 cases of COVID-19 were linked epidemiologically to the first three clusters of circumscribed local transmission in Singapore.
      --
        'Young_et_al_2020
        'Pung_et_al_2020
    / Iran
    subject Iran
      head = Phylogenetic analyses of whole-genome sequencing data identified a distinct SARS-CoV-2 clade linked to travellers returning from Iran to Australia and New Zealand.
      --
        'Eden_et_al_2020
        'Eden_et_al_2020.!a
        'Eden_et_al_2020.!b
    / USA
    subject USA
      head = NYC SARS-CoV-2 epidemic has been mainly sourced from untracked tranmission between US and Europe
      -- USA
        'Holshue_et_al_2020
        'Scott_et_al_2020
        'Rosenberg_et_al_05_08_2020
        'Reiche_et_al_05_29_2020
        'Rosenberg_et_al_05_29_2020
    / Europe
    subject Europe
      head = Early cases were associated with chinese origin, who had travelled to France from China around mid-January, 2020.
      --
        'XavierLescure_et_al_2020
    / Global Epidemiology
    subject GlobalEpidemiology
      head = Undocumented rapid geographic spread of SARS-CoV-2 indicates containment of this virus will be particularly challenging.
      --
        'Lai_et_al_2020
        'Ruiyun_et_al_2020
        'Gudbjartsson_et_al_2020.!a
        'Gudbjartsson_et_al_2020.!c
    / Tranmission Lineage
    subject TranmissionLineage
      head = Phyloepidemiologic approaches have recovered specific directions of human-to-human transmissions and the potential sources for international infected cases.
      --
        'Bhattacharyya_et_al_2020
        'Miller_et_al_2020b
        'Miller_et_al_2020b.!e
        'Miller_et_al_2020b.!f
        'Miller_et_al_2020b.!g
        'Gudbjartsson_et_al_2020.!i
        'Gudbjartsson_et_al_2020.!j
        'Gudbjartsson_et_al_2020.!n
        'Gudbjartsson_et_al_2020.!o


subject module Virus

  / Genetics
  subject module Genetics
    head = Studies shows that SARS-CoV-2 has acquired mutations capable of substantially changing its pathogenicity. The genomic features may explain in part the infectiousness and transmissibility of SARS-CoV-2 in humans.
    -- Genetic Diversity
      'Phan_et_al_2020b
      'Paraskevis_et_al_2020
      'Paraskevis_et_al_2020.!a
      'Paraskevis_et_al_2020.!b
      'Paraskevis_et_al_2020.!c
      'Lu_et_at_2020
      'Lu_et_at_2020.!a
      'Lu_et_at_2020.!b
      'Lu_et_at_2020.!c
      'Lu_et_at_2020.!d
      'Yao_et_al_04_23_2020
    -- Gene Expression
      'King_et_al_2020
      'King_et_al_2020.!a

  / Structure
  subject module Structure
    head = SARS-CoV-2 has four structural proteins, S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. Structure gives clue about the mechanism of cell entry, replication.
    --
      'Walls_et_al_2020
      'Wrapp_et_al_2020
      'Coutard_et_al_2020
      'Benvenuto_et_al_2020
      'Wan_et_al_2020
      'Gao_et_al_2020b
      'Gao_et_al_2020b.!a
      'Gao_et_al_2020b.!b
      'Hillen_et_al_05_15_2020
      'Domling_et_al_05_20_2020

  / Entry and Replication
  subject module Entry
    head = SARS-CoV-2 uses the same cellular entry receptor, ACE2, as SARS-CoV. SARS-CoV-2 virion attaches to a target cell, the cell's protease TMPRSS2 cuts open the spike protein of the virus, exposing a fusion peptide in the S2 subunit, and the host receptor ACE2.
    >>> Replication
      The virion then releases RNA into the cell and forces the cell to produce and disseminate copies of the virus, which infect more cells.
    -- ACE2 and TMPRSS2
      'Hoffman_et_al_2020
      'Matsuyama_et_al_2020
      'Stawiski_et_al_2020
      'Wan_et_al_2020.!a
      'Chen_et_al_05_19_2020
      'Puelles_et_al_05_13_2020
      'Subbarao_et_al_05_19_2020.!d
      'Meinhardt_et_al_06_04_2020
    -- Neuropilin
      'Daly_et_al_06_05_2020
    -- Temperature Depence
      'Vkovski_et_al_2020
      'Vkovski_et_al_2020.!a

  / Shedding
  subject module Shedding
    head = Viral shedding may begin 2 to 3 days before the appearance of the first symptoms. Duration of the viral shedding varies signifcantly and may depend on severity.

    / Viral Shedding
    subject ViralShedding
      head = Based on studies SARS-CoV-2 can actively replicate in upper respiratory tract, and is shed for a prolonged time after symptoms end, including in stool.
      >>>
        Viral RNA can be detected long after the disappearance of infectious virus.
      --
        'Woelfel_et_al_2020
        'He_et_al_2020
        'Wölfel_et_al_2020.!h
        'Woelfel_et_al_2020b.!e
        'Atkinson_et_al_2020
        'Yang_et_al_2020
        'Yang_et_al_2020.!a
        'Yang_et_al_2020.!b
        'Xu_et_al_2020b
        'Woelfel_et_al_2020

    / Viral Load
    subject ViralLoad
      head = Highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset.
      --
        'Liu_et_al_2020c
        'Joynt_et_al_2020
        'Zou_et_al_2020
        'Woelfel_et_al_2020b.!b
        'Woelfel_et_al_2020b.!f
        'Kujawski_et_al_2020.!t
        'Kujawski_et_al_2020.!u
        'Kim_et_al_2020b
        'Kim_et_al_2020b.!b
        'Kim_et_al_2020b.!c
        'Kim_et_al_2020b.!d
        'Pan_et_al_2020b
        'Puelles_et_al_05_13_2020

    --
      ViralShedding
    --
      ViralLoad
    >>>
      Some studies have found that SARS-CoV-2 can be present in Semen and Feces
    --
      Semen
      Feces

    / Semen
    subject Semen
      head = SARS-CoV-2 can be present in the semen of patients with COVID-19, and SARS-CoV-2 may still be detected in semen of recovering patients.
      -- Semen
        'Li_et_al_2020d
        'Woelfel_et_al_2020b.!h
        'Woelfel_et_al_2020b.!i

    / Feces
    subject Feces
      head = Studies have found prolonged presence of SARS-CoV-2 viral RNA in fecal samples tho the research on its infectiousness is still ongoing.
      -- Feces
        'Wu_et_al_2020d
        'Wu_et_al_2020d.!a
        'Wu_et_al_2020d.!b
        'Wu_et_al_2020d.!d
        'Pan_et_al_2020b.!f

  / Tranmission
  subject module Transmission
    head = Human-to-human transmission of SARS-CoV-2 has been confirmed. Transmission occurs primarily via respiratory droplets from coughs and sneezes. Indirect contact via contaminated surfaces is another possible cause of infection.
    / Routes
    subject module Routes
      head = Human to Human contact and Indirect contact via contaminated surfaces is cause of infection. Faecal-oral and Aerosol routes are also suspected to transmit the virus.
      / Surface Transmission
      subject SurfaceTransmission
        head =  Research indicates that the virus may remain viable on plastic  and stainless steel for up to three days, but does not survive on cardboard for more than one day or on copper for more than four hours
        -- Viability
          'van_Doremalen_et_al_2020
          'van_Doremalen_et_al_2020.!b
          'van_Doremalen_et_al_2020.!c
        -- Tranmission
          'Santarpia_et_al_2020
          'Ong_et_al_2020
          'Hamburger_et_al_1948
          'Hamburger_et_al_1948.!j
      / Aerosol Transmission
      subject AerosolTransmission
        head = SARS-CoV-2 viral RNA in air has been detected in several studies. Study found that the majority of these viruses were associated with aerosols.
        -- Viability
          'van_Doremalen_et_al_2020
          'van_Doremalen_et_al_2020.!a
          'Lu_et_al_2020
          'Somsen_et_al_05_27_2020.!a
          'Somsen_et_al_05_27_2020.!b
          'Somsen_et_al_05_27_2020.!c
          'Somsen_et_al_05_27_2020.!d
          'Somsen_et_al_05_27_2020.!e
          'Johnson_et_al_10_05_2012
          'Lin_et_al_01_26_2017
          'Johnson_et_al_06_21_2011
        -- Transmission
          'Asadi_et_al_2019
          'Allen_et_al_05_06_2020
          'Lednicky_et_al_05_22_2020.!a
      / Fecal Transmission
      subject FaecalTransmission
        head = Viral RNA has also been found in stool samples of infected individual.
        --
          'Johnson_et_al_10_05_2012
          'Lin_et_al_01_26_2017
          'Xiao_et_al_05_18_2020
          'Wu_et_al_2020d
    / Environment
    subject module Environment
      head = Studies suggest that temperature has impact on tranmission of COVID-19. Low temperature is beneficial to viral tranmission.
      -- Weather Influence
        'want_et_at_2020
        'luo_et_al_2020
        'Moriyama_et_al_2020
        'Notari_et_al_2020
      -- Air Pollution
        'Wu_et_al_2020c
    subject module Settings
      head = Based on studies COVID-19 has more severe impact on indoor settings over outdoor settings.
      / Nosocomial Transmission
      subject HospitalTransmission
        head = SARS-CoV-2 viral RNA in air has been detected in several studies in hospitals, including at distances greater than 2 m from patients and in outdoor air in crowded areas near a hospital
        --
          'Pan_et_al_2020.!c
          'Liu_et_al_2020bb
      / Indoor Tranmission
      subject IndoorTransmission
        head = Based on studies close contact in the family is the main transmission route of infection.
        -- Household Transmission
          'Jing_et_al_2020.!a
          'Jing_et_al_2020.!b
          'Jing_et_al_2020.!c
          'Jing_et_al_2020.!d
          'Bi_et_al_04_27_2020.!g
          'Bi_et_al_04_27_2020.!h
        -- Indoor Tranmission
          'Ji_et_al_2020
          'Peng-Li_et_al_2020
          'Liu_et_al_2020g
          'Liu_et_al_2020g.!a
          'Liu_et_al_2020h
          'Lu_et_al_2020b
          'Mcmichael_et_al_2020
          'Mcmichael_et_al_2020.!a
          'Pung_et_al_2020
          'Wu_et_al_2020e
          'Qian_et_al_2020
          'Qian_et_al_2020.!c
          'Qian_et_al_2020.!d
          'Qian_et_al_2020.!e
          'Qian_et_al_2020.!i
          'Nishiura_et_al_2020c
          'Nishiura_et_al_2020c.!a
          'Nishiura_et_al_2020c.!b
          'Chan_et_al_2020
          'Scott_et_al_2020.!e
          'Leclerc_et_al_05_01_2020
      / Outdoor Transmission
      subject OutdoorTransmission
        head = Based on data collected so far, Outdoor Tranmission is possible but seems to be rare.
        --
          'Qian_et_al_2020.!h
      / Airline Transmission
      subject AirlineTransmission
        head = The transmission routes in air cabins are probably the close contact route and the formite route.
        --
          'Moser_et_al_1979
          'Olsen_et_al_2003
          'Olsen_et_al_2003.!g
          'Colizza_et_al_2006
          'Colizza_et_al_2006.!a
          'Colizza_et_al_2006.!b
          'Colizza_et_al_2006.!c
          'Lei_et_al_01_06_2020
    / Asymtomatic Tranmission
    subject AsymptomaticTransmission
      head = People can transmit the virus without showing symptoms, but it is unclear how often this happens.
      --
        'Nishiura_et_al_2020
        'Lavezzo_et_al_2020.!e
        'Lavezzo_et_al_2020.!f
        'Bi_et_al_2020.!a
        'Russell_et_al_2020.!a
        'Dong_et_al_2020b
        'He_et_al_2020.!a
    / Superspreader
    subject Superspreaders
      head =  Based on studies the Wuhan market was the site of an early superspreading event. Subsequent research also shows evidence of 20/80 rule of transmission. Model studies have emphasized to include to transmission heterogeneity to accurately portray pathogen dynamics.
      -- Context
        'Lloyd-Smith_et_al_2005
      -- Superspreading in SARS
        'Lee_et_al_2003.!a
        'Shen_et_al_2004
        'Stein_et_al_2011
        'Wang_et_al_2005.!a
        'Wang_et_al_2005.!h
      -- Superspreading in TB
        'Kline_et_al_1995
        'Kline_et_al_1995.!c
        'Kline_et_al_1995.!d
      -- Superspreading Events
        'Hoehl_et_al_2020
        'Hamner_et_al_2020
        'Hamner_et_al_2020.!a
        'Hamner_et_al_2020.!b
        'Hamner_et_al_2020.!c
        'Hamner_et_al_2020.!d
        'Hamner_et_al_2020.!e
        'Hamner_et_al_2020.!f
        'Hamner_et_al_2020.!g
        'Hamner_et_al_2020.!h
        'Adam_et_al_2020
        'Adam_et_al_2020.!a
        'Miller_et_al_2020b.!b
        'Endo_et_al_04_09_2020
    / R<sub>0</sub>
    subject Ro
      head = Estimates of the number of people infected by one person with COVID-19 (the R0) have varied widely. The WHO's initial estimates of the R0 were 1.4-2.5 (average 1.95), however a more recent review found the basic R0 (without control measures) to be higher at 3.28 and the median R0 to be 2.79.
      --
        'Liu_et_al_2020e
        'Liu_et_al_2020e.!a
        'Liu_et_al_2020e.!b
        'Liu_et_al_2020e.!c
        'Liu_et_al_2020e.!d
        'Liu_et_al_2020e.!e
        'Liu_et_al_2020e.!f
        'Heffernan_et_al_2007
        'Jing_et_al_2020.!f
        'Sanche_et_al_2020
        'Sanche_et_al_2020.!d
        'Sanche_et_al_2020.!e
        'Miller_et_al_2020b.!d
        'Salje_et_al_04_20_2020.!d
        'Salje_et_al_04_20_2020.!f
        'Bi_et_al_04_27_2020.!l
        'Bi_et_al_04_27_2020.!m
        'Bi_et_al_04_27_2020.!n
      >>>
        Dispersion factor k number indicates how often an illness occurs and where potential clusters appear. As with the rate of R, it's better to have a low value for k. That would indicate that the potential for distribution is small and the infection can be traced back to a few people or even a single person. But scientists have yet to work out the dispersion factor k for the novel coronavirus.
      --
        'Endo_et_al_04_09_2020

    / Human-to-animal Tranmission
    subject HumanAnimalTransmission
      head = There is some evidence of human-to-animal transmission of SARS-CoV-2, including examples in felids. Some institutions have advised those infected with SARS-CoV-2 to restrict contact with animals.
      --
        'Sun_et_al_2020
        'Chen_et_al_2020b


subject module Disease

  / Incubation Period
  subject IncubationPeriod
    head = The incubation period of the virus is the time between the exposure and the display of symptoms. Current information suggests that the incubation period ranges from 1 to 14 days.
    --
      'Colman_et_al_2018
      'Lessler_et_al_2013
      'Tindale_et_al_2020
      'Nishiura_et_al_2020
      'Linton_et_al_2020
      'J_et_al_2020.!d
      'Jing_et_al_2020.!h
      'Jing_et_al_2020.!j
      'Sanche_et_al_2020.!a

  / Asymtomatic & Presymptomatic Phase
  subject AsymptomaticPhase
    head = A minority of cases do not develop noticeable symptoms at any point in time. These asymptomatic carriers tend not to get tested, and their role in transmission is not fully known.
    --
      'Chan_et_al_2020.!i
      'He_et_al_2020.!b
      'Du_et_al_2020
      'Zou_et_al_2020
      'J_et_al_2020.!e
      'Sutton_et_al_2020.!b
      'Lavezzo_et_al_2020.!b
      'Lavezzo_et_al_2020.!c
      'Mizumoto_et_al_2020
      'Nishiura_et_al_2020
      'Pan_et_al_2020b.!d
      'Graham_et_al_05_16_2020.!b
      'Wu_et_al_04_20_2020
  / Symptomatic Phase
  subject SymptomaticPhase
    head = Fever is the most common symptom. Other symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and myalgia. Additional symptoms such as loss of smell and taste, skin rash, neurological manifestations have also been reported.

    --
      'Ragona_et_al_2020
      'Kluytmans_et_al_2020
      'Chen_et_al_2020d.!c
      'Siddiqi_et_al_2020
      'Siddiqi_et_al_2020.!a
      'Siddiqi_et_al_2020.!b
      'Siddiqi_et_al_2020.!c
      'Siddiqi_et_al_2020.!d
      'Siddiqi_et_al_2020.!e
      'Siddiqi_et_al_2020.!f
      'Siddiqi_et_al_2020.!g
      'Recalcati_et_al_2020
      'Recalcati_et_al_2020.!a
      'Recalcati_et_al_2020.!b
      'Joob_et_al_2020
      'Joob_et_al_2020.!c
      'Sanche_et_al_2020.!b
      'Berlin_et_al_2020.!b
      'Berlin_et_al_2020.!c
      'Berlin_et_al_2020.!d
      'Berlin_et_al_2020.!e
      'Scott_et_al_2020.!a
      'Scott_et_al_2020.!e
      'Zubair_et_al_05_29_2020
      'Chen_et_al_05_19_2020
      'Meinhardt_et_al_06_04_2020
  / Immune Reponse
  subject ImmuneResponse
    head = Clinical Laboratory findings suggest an underline immunopathology. Additional people with COVID-19 and ARDS have classic serum biomarkers of Cytokine release syndrome.
    >>>
      As of now, Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.  Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.
    --
      'Chen_et_al_2020d
      'Chen_et_al_2020d.!d
      'Chen_et_al_2020d.!e
      'Zheng_et_al_2020b
      'Zheng_et_al_2020b.!a
      'Zheng_et_al_2020b.!b
      'Zheng_et_al_2020b.!c
      'Zheng_et_al_2020b.!d
      'Zheng_et_al_2020b.!e
      'Zheng_et_al_2020b.!f
      'Zheng_et_al_2020b.!g
      'Zheng_et_al_2020b.!h
      'Zheng_et_al_2020b.!i
      'Goldman-Israelow_et_al_05_27_2020
      'Braun_et_al_04_22_2020
      'Bert_et_al_05_27_2020
      'Grifoni_et_al_05_04_2020
      'Grifoni_et_al_05_04_2020.!c
      'Mudd_et_al_05_15_2020
      'Mathew_et_al_05_23_2020
      'Vanderheiden_et_al_05_20_2020
      'Subbarao_et_al_05_19_2020.!a
      'Subbarao_et_al_05_19_2020.!b
      'Subbarao_et_al_05_19_2020.!c
      'Thoms_et_al_05_18_2020
      'Merad_et_al_05_06_2020
      'Melo_et_al_05_15_2020
    -- Frontiers
      'Chen_et_al_2009
      'Zhao_et_al_2010
      'Qian_et_al_11_06_2012
      'Chan_et_al_2013
      'Furman_et_al_2015
      'Xu_et_al_2015
      'Niwa_et_al_10_15_2018
      'Okba_et_al_2020.!b
      'Okba_et_al_2020.!c
      'Okba_et_al_2020.!d
      'Merad_et_al_05_06_2020
      'Broggi_et_al_01_06_2020

  / Complications
  subject module Complications
    head = Complications may include pneumonia, ARDS, multi-organ failure, cardiovascular complications, septic shock, neurologic manifestations, endotheliitis. Few recent studies report children developing paediatric multisystem inflammatory syndrome.

    / Cytokine Storms
    subject CytokineStorms
      head = A cytokine storm can be a complication in the later stages of severe COVID‑19. An uncontrolled over-production of soluble markers of inflammation which, in turn, sustain an aberrant systemic inflammatory response, is a major responsible for the occurrence of ARDS.
      --
        'Zheng_et_al_2020
        'Zheng_et_al_2020.!b
        'Siddiqi_et_al_2020.!d
        'Siddiqi_et_al_2020.!e
      -- Lymphopenia
        'Liu_et_al_2020f
        'Liu_et_al_2020f.!a
        'Liu_et_al_2020f.!b
        'Liu_et_al_2020f.!c
        'Liu_et_al_2020f.!d
    / Pneumonia
    subject Pneumonia
      head = The new coronavirus causes severe inflammation in your lungs. People who get pneumonia may also have a condition called acute respiratory distress syndrome (ARDS).   But some who catch the new coronavirus get severe pneumonia in both lungs. COVID-19 pneumonia is a serious illness that can be deadly.
      --
        'Zheng_et_al_2020
        'Li_et_al_2020b
        'Jiang_et_al_04_27_2020
        'Subbarao_et_al_05_19_2020
    / Cardiovascular Dysfunction
    subject CardiacDysfunction
      head = COVID-19 is associated with a number of cardiovascular complications, including myocardial injury and myocarditis, AMI, heart failure, dysrhythmias, and VTE.
      --
        'Siddiqi_et_al_2020.!d
        'Siddiqi_et_al_2020.!f
        'Long_et_al_2020

    / Blood Coagulation
    subject BloodCoagulation
      head = There is growing evidence that COVID-19-infected patients are highly predisposed to developing blood clots, linked blood clotting measurements with actual patient outcomes.
      --
        'Yin_et_al_2020
        'Xiong_et_al_2020
        'Giannis_et_al_2020
        'Zhou_et_al_2020b
        'Cui_et_al_2020
        'Tang_et_al_2020
        'Tang_et_al_2020.!a
        'Siddiqi_et_al_2020.!e
        'Ackermann_et_al_05_21_2020

    / Endothelial Cell Infection
    subject Endothelialcell
      head = Studies supports the theory that COVID-19 can infect blood vessels, which could explain not only the high prevalence of blood clots, strokes, and heart attacks, but also provide an answer for the diverse set of head-to-toe symptoms that have emerged.
      --
        'Varga_al_04_20_2020
        'Ackermann_et_al_05_21_2020

    / Central Nervous System
    subject CNS
      head = The exact mechanism by which SARS-CoV-2 invades the CNS remains unclear. Though there is evidence that SARS-CoV-2 neuroinvasion occurs at the neuro-mucosal interface which explains some of the well-documented neurological symptoms including loss of smell and taste.
      --
        'Meinhardt_et_al_06_04_2020
        'Meinhardt_et_al_06_04_2020.!d
        'Meinhardt_et_al_06_04_2020.!i
        'Meinhardt_et_al_06_04_2020.!j

  / Susceptibility among Variant Population
  subject module VariantPopulations
    head = Disease pervalence and case severity is disproportionate among different age groups, genetics, PregnantWomen, ethnicity, Blood Group, Vitamin D level, Smokers,  Enviornment factors, Variant population based on locations.
    --
      Age
      CoMorbidConditions
      Gender
      PregnantWomen
      GeneticDiversity
      Bloodgroup
      VitaminD
      Ethnicity
      Smokers
      AirPollution
      Clinicalcharacteristics

    / Age
    subject module Age
      head = Children make up a small proportion of reported cases, they are likely to have milder symptoms and a lower chance of severe disease than adults. Data worldwide have shown people older than 60 are more at risk.
      / Children
      subject Children
        head = Children and young people have lower susceptibility to SARS-CoV-2, with a lower odds of being an infected contact. Few recent studies have reported some children developing paediatric multisystem inflammatory syndrome.
        --
          'Zimmermann_et_al_2020
          'Lavezzo_et_al_2020.!d
          'Gudbjartsson_et_al_2020.!g
          'Viner_et_al_05_24_2020
        -- Complications
          'Riphagen_et_al_2020
      / Elderly
      subject Elderly
        head = COVID-19 is more lethal in older patients with co-morbid conditions, and is associated with higher fatality rate.
        --
          'Jing_et_al_2020.!i
          'Chen_et_al_2020d.!b
          'Wu_et_al_2020
          'Porcheddu_et_al_2020
          'Verity_et_al_2020
          'Onder_et_al_2020
          'Tom_et_al_2020.!q
          'Salje_et_al_04_20_2020.!b
          'Rosenberg_et_al_05_29_2020.!g
          'Lee_et_al_05_28_2020.!d
          'DelValle_et_al_05_30_2020.!e
          'Mueller_et_al_05_29_2020
        -- Context
          'Franceschi_et_al_2006
          'Jing_et_al_2009
          'Qian_et_al_2011

    / Gender
    subject Gender
      head = Men are at higher risk of developing severe COVID-19 disease. Some research have investigated the difference might be due to the immune response. There is also supportive evidence of estrogen and a need for clinical trials, as these downregulate TMPRSS2.
      --
        'Chen_et_al_2020d.!a
        'Chen_et_al_2020c
        'Chen_et_al_2020d.!a
        'Chen_et_al_2020d.!b
        'Pan_et_al_2020.!a
        'Simonnet_et_al_2020.!b
        'Gudbjartsson_et_al_2020.!h
        'Williamson_et_al_05_07_2020.!a
        'Salje_et_al_04_20_2020.!c
        'Rosenberg_et_al_05_29_2020.!b
        'Rosenberg_et_al_05_29_2020.!g
        'Lee_et_al_05_28_2020.!d
        'DelValle_et_al_05_30_2020.!e
        'Richardson_et_al_04_22_2020.!d
    / Smokers
    subject Smokers
      head = According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers.
      --
        'Smith_et_al_2020
        'Pan_et_al_2020
        'Pan_et_al_2020.!b
        'Smith_et_al_04_26_2020
    / Pregnant Women
    subject PregnantWomen
      head = Studies reveal that in pregnant women COVID-19 did not lead to maternal deaths. Research has shown no confirmed cases of vertical transmission of SARS-CoV-2 from mothers with COVID-19 to their fetuses though recent case reports demonstrate SARS-CoV-2 infection of the placenta.
      --
        'Dong_et_al_2020
        'Favre_et_al_2020
        'Hosier_et_al_2020
        'Hosier_et_al_2020.!e
        'Sutton_et_al_2020
        'Sutton_et_al_2020.!a
        'Sutton_et_al_2020.!c
        'Schwartz_et_al_2020
        'Schwartz_et_al_2020.!a
        'Schwartz_et_al_2020.!b
        'Schwartz_et_al_2020.!c
        'Schwartz_et_al_2020.!d
        'Schwartz_et_al_2020.!f

    / Clinical characteristics based on location
    subject Clinicalcharacteristics
      head = These studies report epidemiological and clinical characteristics COVID-19 globally. These are published studies on the clinical features, symptoms, complications, and treatments of COVID-19 and help provide guidance in the clinical management of this outbreak.
      --
        'Huang_et_al_2020
        'Chen_et_al_2020c
      -- USA
        'Garg_et_al_2020
        'Garg_et_al_2020.!a
        'Garg_et_al_2020.!b
        'Garg_et_al_2020.!c
        'Garg_et_al_2020.!d
        'Garg_et_al_2020.!e
        'Garg_et_al_2020.!f
        'Lighter_et_al_2020.!c
        'Kujawski_et_al_2020
        'Arentz_et_al_2020
      -- New York
        'Wadhera_et_al_2020
        'Wadhera_et_al_2020.!a
        'Wadhera_et_al_2020.!b
        'Wadhera_et_al_2020.!d
        'Richardson_et_al_04_22_2020
      -- UK
        'Docherty_et_al_2020
      -- China
        'Wang_et_al_2020c
        'Chan_et_al_2020.!e
        'Chan_et_al_2020.!g

    / Air Pollution
    subject AirPollution
      head = Studies show that long-term average exposure to air pollution (fine particulate matter-PM 2.5) increases vulnerability to experiencing the most severe Covid-19 outcomes
      --
        'Wu_et_al_2020c

    / Vitamin D
    subject VitaminD
      head = Based on case study reports, Vitamin D status is significantly associated with clinical outcomes.
      --
        'Alipio_et_al_2020
        'Alipio_et_al_2020.!a
        'Raharusun_et_al_2020
      -- Frontiers
        'Wang_et_al_2005b
        'Lin_et_al_2016
        'Xu_et_al_2017
        'Martineau_et_al_2017
        'Afzal_et_al_2018
        'Afzal_et_al_2018.!a
        'Afzal_et_al_2018.!b
        'Liu_et_al_2018
        'Jolliffe_et_al_2018
        'Cui_et_al_2019
        'Chen_et_al_2019
        'Wortsman_et_al_2020

    / Genetic Diversity
    subject GeneticDiversity
      head = Variation in the human genome plays a role in that susceptibility. Researchers are doing genome-wide association study to look at lots of variants across the human genome that could put certain individuals at high risk of becoming severely ill from the novel coronavirus.
      -- Genetic Diversity
        'Ellinghaus_et_al_06_02_2020
      -- APOE e4 genotype
        'Kuo_et_al_05_26_2020
      --
        'Giorgio_et_al_04_27_2020
      -- HLA
        'Nguyen_et_al_2020
        'Bhattacharyya_et_al_2020
        'Bhattacharyya_et_al_2020.!a
        'Bhattacharyya_et_al_2020.!b
        'Bhattacharyya_et_al_2020.!c
        'Bhattacharyya_et_al_2020.!d
        'Bhattacharyya_et_al_2020.!e
        'Bhattacharyya_et_al_2020.!f
        'Bhattacharyya_et_al_2020.!g

    / Co-Morbid Conditions
    subject module CoMorbidConditions
      head =  Coexisting conditions such as obesity, diabetes, Hypertension, Cancer, HIV and cardiovascular disease could result in severe and even fatal respiratory complications
      --
        Diabetes
        Hypertension
        Obesity
      --
        'Chen_et_al_2020c
        'Sarnak_et_al_2001
        'Zhou_et_al_2020
        'Guan_et_al_2020
        'Guan_et_al_2020.!b
      -- Cardiovascular
        'Li_et_al_2020c
        'Li_et_al_2020c.!a
        'Li_et_al_2020c.!b
        'Li_et_al_2020c.!c
        'Li_et_al_2020c.!d
        'Lee_et_al_05_28_2020.!d
        'DelValle_et_al_05_30_2020.!g
      -- HIV
        'Vizcarra_et_al_05_28_2020
        'Xu_et_al_05_28_2020
      -- Cancer
        'Lee_et_al_05_28_2020
      -- ACE2
        'AlGhatrif_et_al_2020
      -- To avoid complications
        'Liu_et_al_2020d
        'Kim_et_al_2017
        'Peiró_et_al_2020
      subject Diabetes
        --
          'FangFang_et_al_2020
          'Li_et_al_2020c.!b
          'Lee_et_al_05_28_2020.!d
          'DelValle_et_al_05_30_2020.!g
          'Li_et_al_05_29_2020
      subject Hypertension
        --
          'FangFang_et_al_2020
          'Vaduganathan_et_al_2020
          'Bavishi_et_al_2020
          'Liu_et_al_2020d
          'Kim_et_al_2017
          'Peiró_et_al_2020
          'Li_et_al_2020c.!b
          'Lee_et_al_05_28_2020.!d
          'DelValle_et_al_05_30_2020.!g
      subject Obesity
        --
          'Simonnet_et_al_2020
          'Simonnet_et_al_2020.!a
          'Simonnet_et_al_2020.!b
          'Simonnet_et_al_2020.!c
          'Lighter_et_al_2020.!a
          'Lighter_et_al_2020.!b
          'Lighter_et_al_2020.!c

    / Bloodgroup
    subject Bloodgroup
      head = Based on findings, blood type group A have a significantly higher risk for acquiring the coronavirus disease 2019 (COVID-19) compared with non-A blood groups. Additionally, blood group O has a significantly lower risk for the infection compared with non-O blood groups.
      --
        'Zhao_et_al_2020b
        'Ellinghaus_et_al_06_02_2020.!b
        'Ellinghaus_et_al_06_02_2020.!c

    / Ethnicity
    subject Ethnicity
      head = Case Reports from US shows, a greater proportion of deaths due to COVID-19 have occurred among African Americans. Similar issues affect Native American and Latino communities.
      --
        'Williamson_et_al_05_07_2020.!b
        'Rosenberg_et_al_05_29_2020.!c
        'Rosenberg_et_al_05_29_2020.!f
        'DelValle_et_al_05_30_2020.!f
        'Van-Dorn_et_al_04_18_2020.!a

  / Case Fatality Rate & Mortality Rate
  subject module Fatality
    head = Observed CFR is higher in some countries than other may be related to three factors: population age, definition of COVID-19 related death and testing strategies. In addition, the delay between testing and mortality in the numbers of early epidemic is a crucial bias.
    -- CFR
      'Russell_et_al_2020
      'Wu_et_al_2020
      'Hauser_et_al_2020
      'Porcheddu_et_al_2020
      'Onder_et_al_2020
      'Remuzzi_et_al_2020
      'Pan_et_al_2020.!a
      'Lighter_et_al_2020
      'Wadhera_et_al_2020.!a
      'Salje_et_al_04_20_2020.!b
      'Basu_et_al_05_07_2020
    -- Mortality Rate
      'Modig_et_al_2020
      'Berlin_et_al_2020.!e
      'Arentz_et_al_2020.!h
      'Graham_et_al_05_16_2020
      'Banerjee_et_al_05_12_2020
      'Lee_et_al_05_28_2020.!d
      'Richardson_et_al_04_22_2020.!d
      'Richardson_et_al_04_22_2020.!g
      'Richardson_et_al_04_22_2020.!n
      'Hauser_et_al_2020
    -- Prediction
      'Yan_et_al_05_14_2020
      'Grewelle_et_al_05_18_2020

  / Immunity
  subject module Immunity
    head = Studies have shown that recovered patients have protective immunity that prevents them from being reinfected. The duration of immunity still remains unclear. However, new studies indicate a lack of sufficient long-lasting protective antibodies post SARS-CoV-2 infection.
    / Antibodies
    subject Antibodies
      head = Most of the studies show that people who have recovered from infection have antibodies to the virus. Though recent papers have observed lack of sufficient "long-lasting protective antibodies" post SARSCoV2 infection.
      >>>
        IgM antibodies to SARS-CoV-2 are generally detectable several days after initial infection, although levels over the course of infection are not well characterized.IgG antibodies generally become detectable 10–14 days after infection, sometimes earlier, and normally peak around 28 days after infection onset.
      -- SARS-CoV2
        'Jiang_et_al_2020
        'Wu_et_al_2020b
        'Zhang_et_al_2020g
        'Amanat_et_al_2020
        'Lassaunière_et_al_2020
        'Lv_et_al_06_02_2020
      -- How long does your immunity last
        'Zhao_et_al_2020
        'Zhao_et_al_2020.!a
        'Zhao_et_al_2020.!b
        'Zhao_et_al_2020.!c
        'Wu_et_al_2007
        'Wu_et_al_2007.!a
        'Ka_et_al_1990
      >>> Studies of antibodies on other coronavirus
      -- MERS
        'Alshukairi_et_al_2016
      --
        'Callow_et_al_1990
      -- SARS
        'Liu_et_al_2019

    / Reinfection
    subject Reinfection
      head = Based on studies, the reinfection can not occur if neutralizing antibodies are produced at primary infection. Reinfection immunity to adult has been studied using laboratory animal models, the results showed that animal models become resistant to reinfection.
      --
        'Bao_et_al_2020
        'Bao_et_al_2020.!a
        'Wölfel_et_al_2020
        'Wölfel_et_al_2020.!h
        'Wölfel_et_al_2020.!i
        'Amanat_et_al_2020.!b
        'Jiang_et_al_04_27_2020.!b

    / Relapse
    subject Relapse
      head = Reports suggest that the tests which declared relapse were giving false negative reactions. Other findings hint that the diagnostic tests are picking up on the genetic material from noninfectious viruses, which means people are not infected nor they are infectious to others.
      --
        'Tom_et_al_2020
        'Tom_et_al_2020.!h
        'Yuan_et_al_2020.!h
        'Yuan_et_al_2020.!i
        'Yuan_et_al_2020.!j
        'Yuan_et_al_2020.!k
        'Lan_et_al_2020
        'Xie_et_al_2020


# Past infection, Active infection, Risk Factors
subject module Diagnostics

  subject module Methods
    subject Serology
      --
        'McLeish_et_al_2011
        'McLeish_et_al_2011.!a
        'Jiang_et_al_2020
        'Netto_et_al_2017
        'Stadlbauer_et_al_2020
        'Mcintosh_et_al_1970
        'Zhang_et_al_2020g
        'Amanat_et_al_2020
        'Amanat_et_al_2020.!c
        'Amanat_et_al_2020.!f
        'Lassaunière_et_al_2020.!a
        'Lassaunière_et_al_2020.!b
        'Lassaunière_et_al_2020.!c
        'Lassaunière_et_al_2020.!d
        'Lassaunière_et_al_2020.!e
        'Thompson_et_al_2020
        'Thompson_et_al_2020.!a
        'Lipsitch_et_al_2020
        'Okba_et_al_2020
        'Wu_et_al_04_20_2020
        'Muruato_et_al_05_22_2020
        'Weissleder_et_al_06_03_2020
        'Watson_et_al_05_12_2020
        'Sethuraman_et_al_05_06_2020
        'Weissleder_et_al_06_03_2020
      -- Seroprevalence
        'Salje_et_al_04_20_2020.!j
        'Stringhini_et_al_05_06_2020
        'Wang-To_et_al_06_03_2020
    subject PCR
      -- Limitations of PCR and RT-PCR
        'Joynt_et_al_2020
        'Fang_et_al_2020
        'Yuan_et_al_2020
        'Weissleder_et_al_06_03_2020
        'Woloshin_et_al_06_05_2020
        'Xiao_et_al_2020
        'Lan_et_al_2020
      -- PCR
        'Wölfel_et_al_2020
        'Babady_et_al_2017
        'Huang_et_al_2017
        'Beckmann_et_al_2016
        'Watson_et_al_05_12_2020
        'Sethuraman_et_al_05_06_2020
        'Tom_et_al_2020
      -- RT- PCR
        'Chut_et_al_2011
        'Bullard_et_al_05_22_2020
      -- Saliva
        'Wyllie_et_al_2020
        'Wyllie_et_al_2020.!a
        'Wyllie_et_al_2020.!b
        'Wyllie_et_al_2020.!c
        'Wyllie_et_al_2020.!d
        'Wyllie_et_al_2020.!e
        'Williams_et_al_2020
        'Williams_et_al_2020.!a
        'Williams_et_al_2020.!c
    / CT Scan
    subject CT
      -- CT
        'Inui_et_al_2020
        'Inui_et_al_2020.!a
        'Wang_et_al_2020b
        'Xie_et_al_2020

  # Targets
  subject Frontiers
    -- LDH
      'Han_et_al_2020
    -- Immune Profiling
      'Mathew_et_al_05_23_2020.!a
      'Mathew_et_al_05_23_2020.!b
    -- Disease Severity
      'Chen_et_al_04_06_2020
      'Chen_et_al_02_08_2020
      'DelValle_et_al_05_30_2020
      'DelValle_et_al_05_30_2020.!m

subject module Mitigation
  # Mitigation / Infection Prevention
  subject module IndividualMitigation
    subject SocialDistancing
      -- Six-foot rule
        'Feigin_et_al_1982
    subject HandWashing
      --
        'Ryan_et_al_2001
        'Jefferson_et_al_2008
        'Jefferson_et_al_2008.!a
    subject Sanitization
    / Protective Equipments & Surfaces
    subject ProtectiveDevices
      --
        'Jefferson_et_al_2008
      -- Face Mask
        'Yan_et_al_2019
        'Tracht_et_al_2010
        'Reza_et_al_2011
        'Leung_et_al_2020
        'Jing_et_al_2020.!k
        'Howard_et_al_05_13_2020
        'Bae_et_al_04_06_2020
        'Strasser_et_al_05_22_2020
        'Chu_et_al_06_01_2020
      -- PPE
        'Ling_et_al_2020.!b
      -- Gloves
        'King_et_al_04_24_2020

  # / Network Prevention / Containment
  subject module CommunityMitigation

    subject SocialNetwork
      --
        'Keeling_et_al_2005
        'Keeling_et_al_2005.!a
        'Keeling_et_al_2005.!b
        'Keeling_et_al_2005.!c
        'Mossong_et_al_2008
        'Christakis_et_al_2010
        'Fu_et_al_2017
        'gracia_et_al_2017
        'gracia_et_al_2017b
    subject Quarantine
      -- Quarantine
        'Dandekar_et_al_2020
        'Xia_et_al_2020
        'Cowling_et_al_2020
        'Pan_et_al_2020.!e
        'Jing_et_al_2020.!e
        'Jing_et_al_2020.!f
        'Jing_et_al_2020.!g
        'Jing_et_al_2020.!l
        'Woelfel_et_al_2020b.!i
        'Sanche_et_al_2020.!f
        'Chan_et_al_2020.!r
        'Bi_et_al_04_27_2020.!k
    subject SocialDistancing
      --
        'Cowling_et_al_2020
        'Cowling_et_al_2020.!a
        'Cowling_et_al_2020.!b
        'Cowling_et_al_2020.!c
        'Mossong_et_al_2008.!b
        'Lavezzo_et_al_2020.!e
    subject SchoolClosure
      --
        'Sebastiani_et_al_2006
        'Fergusion_et_al_2006
        'Market_et_al_2007
        'Mossong_et_al_2008.!a
        'Kawano_et_al_2015
        'Ciavarella_et_al_2016
        'Cowling_et_al_2020.!d
    subject ContactTracing
      --
        'Ferretti_et_al_2020
        'J_et_al_2020.!f
        'Lavezzo_et_al_2020.!f
        'Jing_et_al_2020.!a
        'Sanche_et_al_2020.!f
        'Bi_et_al_04_27_2020.!i
    subject Sewage
      --
        'Lodder_et_al_2020
        'Medeema_et_al_2020
        'Lodder_et_al_2012
      -- Sewage Sludge
        'Peccia_et_al_2020
    subject HerdImmunity
      # In ZIKV population exposure to virus didn't let 2nd wave
      --
        'Netto_et_al_2017
      --
        'John_et_al_2000
        'Ferrari_et_al_2006
        'Fine_et_al_2011
        'Langwig_et_al_2017
        'Logan_et_al_2018
      --
        'Gomes_et_al_2020
        'Britton_et_al_2020
        'Sanche_et_al_2020.!e
        'Dufresne_et_al_2020
        'Dufresne_et_al_2020.!a
        'Dufresne_et_al_2020.!e
        'Dufresne_et_al_2020.!f
        'Dufresne_et_al_2020.!g
        'Dufresne_et_al_2020.!h
        'Adam_et_al_2020.!f
        'Miller_et_al_2020b.!c
    subject Frontiers
      -- Model to prevent 2nd outbreak
        'Zhang_et_al_2020b
      -- Using ACE 2 to predict Susceptibility
        'Stawiski_et_al_2020
      -- Airborne Mitigation
        'Morawska_et_al_05_27_2020

      >>> Countries Mitigation Measures
      -- How china did it?
        'J_et_al_2020.!i
        'Pan_et_al_2020
        'Pan_et_al_2020.!d
        'Pan_et_al_2020.!e
        'Lai_et_al_2020b.!b
        'Lai_et_al_2020b.!c
        'Lai_et_al_2020b.!d
        'Lai_et_al_2020b.!e
        'Lai_et_al_2020b.!g
        'Lai_et_al_2020b.!h
        'Lai_et_al_2020b.!i
        'Lai_et_al_2020b.!j
        'Lai_et_al_2020b.!k
        'Zhang_et_al_04_29_2020
      -- Italy
        'Lavezzo_et_al_2020.!a
      -- France
        'Salje_et_al_04_20_2020
      -- UK
        'Davies_et_al_06_02_2020

  subject Nosocomial
    --
      'Wang_et_al_2005.!a
      'Wang_et_al_2005.!e
      'Wang_et_al_2005.!f
      'Wang_et_al_2005.!g
      'Lee_et_al_2003.!b
      'Seto_et_al_2003
      'Seto_et_al_2003.!a
      'Seto_et_al_2003.!b
      'Seto_et_al_2003.!c
      'Seto_et_al_2003.!d
      'Seto_et_al_2003.!e
      'Boyce_et_al_2007
      'Boyce_et_al_2007.!a
      'Boyce_et_al_2007.!b
      'Boyce_et_al_2007.!c
      'Salgado_et_al_2015
      'Ling_et_al_2020
      'Ling_et_al_2020.!a
      'Ling_et_al_2020.!b
      'Ling_et_al_2020.!c
      'Ling_et_al_2020.!d
      'J_et_al_2020.!g
      'J_et_al_2020.!h
      'J_et_al_2020.!j
      'Pan_et_al_2020.!e
      'Liu_et_al_2020bb.!a
      'Somsen_et_al_05_27_2020.!f
      'Liu_et_al_2020

  # Inactivating Agents / or Disinfection of envioronmental surfaces
  subject Disinfection
    -- UVC
      'Welch_et_al_2018
      'Elikaei_et_al_2006
      'Darnell_et_al_2004.!a
    -- UV Light Frontiers
      'SaifAddin_et_al_2020
    -- Copper
      'Han_et_al_2005
      'Sarah_et_al_2015
      'Sarah_et_al_2015.!a
      'Sarah_et_al_2015.!b
      'Sarah_et_al_2015.!c
      'Michels_et_al_2015
      'Michels_et_al_2015.!a
      'Michels_et_al_2015.!b
      'Dessauer_et_al_2016
      'Noyce_et_al_2007
      'Noyce_et_al_2007.!a

  # New Subject as Prospects
  # 'Darnell_et_al_2004

# / Medical Interventions # Disease Control
subject module Remediation
  -- Potential Interventions
    'Li_et_al_2020
    'Zhang_et_al_2020e
  -- Nasal Irrigation
    'Bastier_et_al_2015
  -- Clinical Course
    'Berlin_et_al_2020
    'Berlin_et_al_2020.!g
    'Berlin_et_al_2020.!h
    'Berlin_et_al_2020.!i
    'Berlin_et_al_2020.!j
    'Berlin_et_al_2020.!k
    'Berlin_et_al_2020.!l
    'Berlin_et_al_2020.!m
    'Berlin_et_al_2020.!n
    'Berlin_et_al_2020.!o
    'Berlin_et_al_2020.!p
    'Berlin_et_al_2020.!q
    'Berlin_et_al_2020.!r
    'Berlin_et_al_2020.!s
    'Berlin_et_al_2020.!u
    'Berlin_et_al_2020.!v
    'Berlin_et_al_2020.!w
  -- Clinical Course Blood coagulation
    'Song_et_al_2020
    'Song_et_al_2020.!a
    'Song_et_al_2020.!b
    'Song_et_al_2020.!c
    'Song_et_al_2020.!d
    'Song_et_al_2020.!e
    'Song_et_al_2020.!f
    'Song_et_al_2020.!g
    'Song_et_al_2020.!h
    'Song_et_al_2020.!i
    'Song_et_al_2020.!j
    'Song_et_al_2020.!k
    'Song_et_al_2020.!l
    'Song_et_al_2020.!m
    'Song_et_al_2020.!n
    'Song_et_al_2020.!o
    'Song_et_al_2020.!p
    'Song_et_al_2020.!q
    'Song_et_al_2020.!r
    'Berlin_et_al_2020.!t
  -- Neuroinvasion
    'Zubair_et_al_05_29_2020.!a
    'Zubair_et_al_05_29_2020.!b
    'Zubair_et_al_05_29_2020.!c
    'Zubair_et_al_05_29_2020.!d
    'Zubair_et_al_05_29_2020.!e
    'Zubair_et_al_05_29_2020.!f


  --
    Vaccines
    Therapeutics
    Frontiers
    Ventilators

  subject Vaccines
    -- Frontiers
      'Watanabe_et_al_2020
      'Wu_et_al_2020b
      'Kames_et_al_2020
      'Kames_et_al_2020
      'Peeples_et_al_2020
      'Quinlan_et_al_2020
      'Iwasaki_et_al_2020
      'Iwasaki_et_al_2020.!a
      'Wan_et_al_2019
      'Grifoni_et_al_05_04_2020.!a
      'Grifoni_et_al_05_04_2020.!b
      'Kaslow_et_al_05_07_2020
      'Breiman_et_al_05_21_2020
      'Dieterle_et_al_05_20_2020
      'Weng_et_al_05_19_2020
      'Robbiani_et_al_05_22_2020
      'Lv_et_al_06_02_2020
    --
      Process
      Prospects

    subject Process
    subject Prospects
      -- MMR, measles
        'Franklin_et_al_2020
      -- PiCoVacc
        'Gao_et_al_2020
      -- RNA Vaccine
        'Amanat_et_al_2020b.!a
        'Amanat_et_al_2020b.!b
        'Erasmus_et_al_05_28_2020
      -- DNA Vaccine
        'Amanat_et_al_2020b.!c
        'Amanat_et_al_2020b.!d
        'Smith_et_al_02_25_2020
        'Smith_et_al_05_08_2020
        'Yu_et_al_05_20_2020
        'Chandrashekar_et_al_05_20_2020
      -- Recombinant Protien Vaccine
        'Amanat_et_al_2020b.!e
        'Amanat_et_al_2020b.!f
      -- Viral vector-based vaccine
        'Amanat_et_al_2020b.!g
        'Amanat_et_al_2020b.!h
      -- Live Attennuated Vaccine
        'Amanat_et_al_2020b.!i
        'Amanat_et_al_2020b.!j
      -- Inactivated Vaccine
        'Amanat_et_al_2020b.!k
        'Amanat_et_al_2020b.!l
      --
        BCG
      subject BCG
        --
          'Berg_et_al_2020
          'Arts_et_al_2020
          'Darrah_et_al_2020
          'Miller_et_al_2020
          'Higgins_et_al_2016
          'Netea_et_al_2016
          'Kleinnijenhuis_et_al_2012
          'Hegarty_et_al_2020
          'ONeill_et_al_2020
        -- Counter
          'Hamiel_et_al__05_13_2020

  subject Therapeutics

    subject Antivirals
      -- Generic papers
        'hui_et_al_2020
        'Sheahan_et_al_2020
      --
        Remdesivire
        LopinavirRitonavir
        Chloroquine
        Hydroxychloroquine
        HydroxychloroquineWithZinc
        HydroxychloroquineWithAzithromycin
        Niclosamide
        Nitazoxanide
        aketoamideinhibitor
      subject Remdesivire
        --
          'Sheahan_et_al_2017
          'Wang_et_al_2020
          'agostini_et_al_2018
          'grein_et_al_2020
          'Beigel_et_al_2020
          'Berlin_et_al_2020.!w
          'Kujawski_et_al_2020.!d
          'Kujawski_et_al_2020.!i
      / Lopinavir-Ritonavir
      subject LopinavirRitonavir
        --
          'Lim_et_al_2020
          'Cao_et_al_2020
          'Cvetkovic_et_al_2012
      subject Chloroquine
        --
          'Savarino_et_al_2003
          'Davis_et_al_2003
          'Vincent_et_al_2005
          'Cortegiani_et_al_2020
          'Wang_et_al_2020

      subject Hydroxychloroquine
        --
          'Liu_et_al_2020b
          'Yao_et_al_2020
          'Mahevas_et_al_2020
          'Geleris_et_al_05_27_2020

      / Hydroxychloroquine with Zinc
      subject HydroxychloroquineWithZinc
      / Hydroxychloroquine with Azithromycin
      subject HydroxychloroquineWithAzithromycin
        --
          'Gautret_et_al_2020
      subject Niclosamide
        --
          'Xu_et_al_2020
      subject Nitazoxanide
        --
          'Rossignol_et_al_2014
          'Wu_et_al_2004
      / a-ketoamide inhibitor
      subject aketoamideinhibitor
        --
          'Zhang_et_al_2020c
          'Zhang_et_al_2020
    / Host modifiers and Immune-Based Therapy
    subject HostModifiers
      subject ConvalescentPlasma
        --
          'Jenkins_et_al_2015
          'Chen_et_al_2020
          'Duan_et_al_2020
          'Duan_et_al_2020.!a
          'Duan_et_al_2020.!b
          'Duan_et_al_2020.!c
          'Shen_et_al_2020
          'Shen_et_al_2020.!a
          'Liu_et_al_2020i

        -- Counter
          'Marano_et_al_2016
        -- Limitations
          'Wong_et_al_2010
      # (e.g., Anakinra)
      / Interleukin-1 (IL-1) Inhibitors
      subject IL1
        --
          'Evavold_et_al_2017
          'Evavold_et_al_2017.!a
          'Siddiqi_et_al_2020.!g
          'Conti_et_al_03_14_2020
      # (Sarilumab, Siltuximab, Tocilizumab)
      / Interleukin-6 (IL-6) Inhibitors
      subject IL6
        --
          'Siddiqi_et_al_2020.!g
          'Kimmig_et_al_05_20_2020
          'Conti_et_al_03_14_2020
          'DelValle_et_al_05_30_2020.!r
          'DelValle_et_al_05_30_2020.!s
      # Other Immunomodulators
      subject Interferons
        --
          'Vanderheiden_et_al_05_20_2020.!a
        #  (Alpha, Beta)
      subject JanusKinaseInhibitors
      subject CytokineInhibitors
        --
          'Konig_et_al_04_18_2020
          'DelValle_et_al_05_30_2020
        #  (e.g., Baricitinib)
    #  / Concomitant Medications
    / Anti-Inflammatories
    subject AntiInflammatories
      / ACE-2 Inhibitors
      subject ACEInhibitors
        --
          'Zhang_et_all_2020b
          'Zhang_et_al_2020f
      / ARBs
      subject ARBs
        -- ARB
          'Liu_et_al_2020d
          'Zhang_et_al_2020f
      subject Corticosteroids
        --
          'Berlin_et_al_2020.!x
          'Berlin_et_al_2020.!y
          'Xu_et_al_2020b.!k
      / HMG-CoA Reductase Inhibitors (Statins)
      subject Statins
        --
          'Hothersall_et_al_2006
          'Singla_et_al_2012
          'Mansur_et_al_2015
          'Mansur_et_al_2015.!c
          'Mansur_et_al_2015.!d
          'Mansur_et_al_2015.!g
          'Mansur_et_al_2015.!h
      / Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      subject NSAIDs
        --
          'Llor_et_al_2013
          'Voiriot_et_al_2019
  subject Frontiers
    # immune response of bats
    -- Bats
      'Xie_et_al_2018
      'Zhang_et_al_2013
      'Najjar_et_al_2015
      'Najjar_et_al_2015.!g
      'Banerjee_et_al_2017
      'Kacprzyk_et_al_2017
      'Mandl_et_al_2018
      'Mandl_et_al_2018.!a
      'Mandl_et_al_2018.!b
      'Mandl_et_al_2018.!c
      'Benfield_et_al_2019
      'Banerjee_et_al_2020
      'Pavlovich_et_al_2018
      'Skirmuntt_et_al_05_12_2020
    -- Zinc Inhibitor
      'Velthuis_et_al_2010
    -- Zinc
      'Beck_et_al_1997
      'Hemilä_et_al_2017
    # Not relevant here but has some correlation
    -- Quercetin
      'Yi_et_al_2004
      'Chondrogianni_et_al_2010
    -- Innate Immunity
      'Takeuchi_et_al_2009
      'Iwasaki_et_al_2014
      'Netea_et_al_2016
      'Pillai_et_al_2016
      'Broggi_et_al_01_06_2020
      'Niwa_et_al_10_15_2018
    -- SARS and MERS
      'Chen_et_al_2009
      'Zhao_et_al_2010
      'Zumla_et_al_2016
      'Alharbi_et_al_11_19_2019
      'Shan-Shi_et_al_06_05_2019
    -- Genetic Risk ?
      'Stawiski_et_al_2020
      'Batlle_et_al_2020
    -- Peptides
      'Fukushi_et_al_2005
    -- Pyroptosis
      'Evavold_et_al_2017
      'Shi_et_al_2019.!a
      'Shi_et_al_2019.!b
      'Shi_et_al_2019.!c
      'Shi_et_al_2019.!d
      'Wu_et_al_2019
      'Wu_et_al_2019.!a
      'Wu_et_al_2019.!b
      'Wu_et_al_2019.!c
      'Wu_et_al_2019.!d
      'Wu_et_al_2019.!e
      'Wu_et_al_2019.!f
      'Wu_et_al_2019.!g
      'Wu_et_al_2019.!h
      'Wu_et_al_2019.!i
      'Wu_et_al_2019.!j
    -- Antiviral compound
      'Das_et_al_2020
    -- ISG15
      'Perng_et_al_2018
      'Perng_et_al_2018.!a
      'Perng_et_al_2018.!b
      'Perng_et_al_2018.!c
      'Perng_et_al_2018.!d
      'Perng_et_al_2018.!e
      'Perng_et_al_2018.!f
      'Perng_et_al_2018.!g
      'Shaabani_et_al_2020
      'Shaabani_et_al_2020.!a
      'Shaabani_et_al_2020.!b
      'Shaabani_et_al_2020.!c
      'Shaabani_et_al_2020.!d
      'Shaabani_et_al_2020.!e
      'Shaabani_et_al_2020.!f
      'Shaabani_et_al_2020.!g
      'Shaabani_et_al_2020.!h
      'Shaabani_et_al_2020.!i
    --
      'Zheng_et_al_2020b.!j
    -- Estrogen Related Therepy
      'Mishra_et_al_2018
      'Sutton_et_al_2020
      'Schwartz_et_al_2020
      'Schwartz_et_al_2020.!a
      'Schwartz_et_al_2020.!b
    -- HLA
      'Lin_et_al_2003
      'Blackwell_et_al_2009
      'Paul_et_al_2013
      'Nguyen_et_al_2020
    -- Deep Learning
      'Stokes_et_al_2020
      'Stokes_et_al_2020.!a
    --
      'Monteil_et_al_2020
    -- Cross Neutralization
      'Ju_et_al_05_26_2020
    -- Monoclonal Antibodies
      'Shi_et_al_05_26_2020
    -- Vesicular stomatitis virus
      'Dieterle_et_al_05_20_2020
      'Fukushi_et_al_2005
      'Daly_et_al_06_05_2020.!f
    -- Cytokine Profiling
      'DelValle_et_al_05_30_2020
    --
      Proteases

    subject Proteases
      --
        'Hoffmann_et_al_2020
  subject Ventilators
    -- Side effects
      'Dreyfuss_et_al_1998
      'Soni_et_al_2008
    --
      'Ferreira_et_al_04_19_2020
      'Richardson_et_al_04_22_2020.!f
      'Richardson_et_al_04_22_2020.!l

subject module Projections

  --
    'Woolhouse_et_al_1997
    'Lloyd-Smith_et_al_2005
    'Kissler_et_al_2020
    'Vespignani_et_al_2020
  -- If you remove early quarantine cases will increase
    'Dandekar_et_al_2020
  --
    'Netto_et_al_2017.!e
  -- Mitigation
    'Chikina_et_al_2020
  -- Non-pharmaceutical intervention
    'Flaxman_et_al_2020
    'Flaxman_et_al_2020.!a
    'Flaxman_et_al_2020.!b
    'Flaxman_et_al_2020.!c
    'Flaxman_et_al_2020.!d
    'Flaxman_et_al_2020.!e


subject module PublicPolicy
  --
    SocialBehavior
  --
    'Wadhera_et_al_2020
    'Lai_et_al_2020b
    'Lai_et_al_2020b.!f
    'Adam_et_al_2020.!b
    'Adam_et_al_2020.!c
    'Adam_et_al_2020.!d
    'Adam_et_al_2020.!e
    'Adam_et_al_2020.!h
    'Adam_et_al_2020.!i
    'Adam_et_al_2020.!j
    'Tom_et_al_2020
    'Siedner_et_al_05_29_2020
    'Dohery_et_al_05_29_2020
    'Van-Dorn_et_al_04_18_2020
  -- Mental Health
    'Kantor_et_al_05_28_2020
  -- Seroprevalence
    'Bryant_et_al_05_19_2020


  -- Community level antibody testing
    'Lipsitch_et_al_2020

  subject SocialBehavior
    --
      'Bavel_et_al_2020
      'Reyna_et_al_06_02_2020
